Onconova Therapeutics Inc
NASDAQ:TRAW
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Onconova Therapeutics Inc
Net Income
Onconova Therapeutics Inc
Net Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Onconova Therapeutics Inc
NASDAQ:TRAW
|
Net Income
-$166.5m
|
CAGR 3-Years
-118%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Net Income
$26.8B
|
CAGR 3-Years
28%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Net Income
$7.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
16%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Net Income
$7.8B
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Net Income
$18.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
32%
|
CAGR 10-Years
15%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Net Income
$20.6B
|
CAGR 3-Years
49%
|
CAGR 5-Years
27%
|
CAGR 10-Years
24%
|
|
Onconova Therapeutics Inc
Glance View
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. The company is headquartered in Newtown, Pennsylvania and currently employs 14 full-time employees. The company went IPO on 2013-07-25. The company has molecularly targeted agents designed to disrupt specific cellular pathways for cancer cell proliferation. The company has the two clinical-stage programs: narazaciclib (ON 123300), which is a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib administered alone or in combination for the treatment of solid tumors. Narazaciclib is a multi-targeted kinase inhibitor targeting cyclin-dependent kinases (CDK) 2, 4, 6, and 9, AMPK related protein kinase 5 (ARK5), and colony-stimulating factor 1 receptor (CSF1R). The company is supporting investigator-initiated studies (ISS) that are exploring the use of rigosertib for cancers driven by mutated Ras genes, including a Phase 1/2a study of rigosertib in combination with a PD-1 inhibitor.
See Also
What is Onconova Therapeutics Inc's Net Income?
Net Income
-166.5m
USD
Based on the financial report for Dec 31, 2024, Onconova Therapeutics Inc's Net Income amounts to -166.5m USD.
What is Onconova Therapeutics Inc's Net Income growth rate?
Net Income CAGR 3Y
-118%
Over the last year, the Net Income growth was -779%. The average annual Net Income growth rates for Onconova Therapeutics Inc have been -118% over the past three years .
